Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Phosphoproteins – e.g. – phosvitin – vitellogenin – etc.
Reexamination Certificate
2005-08-02
2005-08-02
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Phosphoproteins, e.g., phosvitin, vitellogenin, etc.
C530S300000, C530S350000, C424S185100, C536S023500
Reexamination Certificate
active
06924358
ABSTRACT:
A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and/or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
REFERENCES:
patent: 6262333 (2001-07-01), Endege et al.
patent: 6569662 (2003-05-01), Tang et al.
patent: 2003/0223997 (2003-12-01), Challita-Eid et al.
patent: WO 99/33982 (1999-07-01), None
patent: WO 99/38972 (1999-08-01), None
patent: WO 99/64576 (1999-12-01), None
patent: WO 01/02568 (2001-01-01), None
patent: WO 01/22920 (2001-04-01), None
patent: WO 01/53312 (2001-07-01), None
patent: WO 01/66753 (2001-09-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 02/083876 (2002-10-01), None
patent: WO 02/095009 (2002-11-01), None
Lerner. Nature 1982; 299:592-596, see p. 595-596.
Mikayama et al. PNAS, 1993. 90: 10056-10060.
Burgess et al J Cell Biol. 111:2129-2138, 1990.
Lazar et al. Mol Cell Biol. 8:1247-1252, 1988.
Ngo et al, The Protein Folding Problem and Tertiary Structure Prediction, 1994. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Attwood Science 2000; 290:471-473.
Skolnick et al. Trends in Biotech. 2000; 18(1):34-39.
Metzler et al. Nature Structural Biol. 1997; 4:527-531.
Carninci, P. et al. (1999). “High-Efficiency Full-Length cDNA Cloning” Chapter 2 incDNA Preparation and Characterization—Methods in Enzymology, Weissman, S.M. ed. Academic Press, Inc. 303:19-44.
Carninci, P. et al. (2000), “Normalization and Subtraction of Cap-Trapper-Selected cDNAs to Prepare Full-Length cDNA Libraries for Rapid Discovery of New Genes,”Genome Research10:1617-1630.
GenBank Accession No. BAB27765 located at <http://www.ncbi.nlm.nih.gov/entrez/viewe.fcgi?db=protein&val=12847934> last visited on Nov. 28, 2004, three pages.
GenBank Accession No. NP_115493 located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=14149769> last visited on Nov. 28, 2004, two pages.
Shibata, K. et al. (2000). “RIKEN Integrated Sequence Analysis (RISA) System—384-Format Sequencing Pipeline with 384 Multicapillary Sequencer,”Genome Research10:1757-1771.
The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team (Dec. 5, 2002). “Analysis of the Mouse Transcriptome Based on Functional Annotation of 60,770 Full-Length cDNAs,”Nature420:563-573.
The RIKEN Genome Exploration Research Group Phase II Team and the FANTOM Consortium (Feb. 8, 2001). “Functional Annotation of a Full-Length Mouse cDNA Collection,”Nature409:685-690.
Tsubouchi, H. et al. (May 2002). “The Mnd1 Protein Forms a Complex with Hop2 to Promote Homologous Chromosome Pairing and Meiotic Double-Strand Break Repair,”Molecular and Cellular Biology22(9):3078-3088.
DGENE Record Accession No. AAX98924 for WO 99/33982, two pages.
DGENE Record Accession No. AAX99020 for WO 99/33982, two pages.
GenBank Accession No. AY028916 created Mar. 29, 2001, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=13488608> last visited on Nov. 15, 2004.
GenBank Accession No. BE513408 created Aug. 4, 2000, located at <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=9720620> last visited on Nov. 15, 2004.
Supplementary Partial European Search Report mailed Oct. 6, 2004, for European Patent Application No. 02723291.7, filed Feb. 28, 2002, 7 pages.
EMBL Accession No. AAM40043, created on Oct. 21, 2001, European Search Report Reference No. XP 002297423, two pages.
EMBL Accession No. AAZ80011, created on Apr. 7, 2000, European Search Report Reference No. XP 002297421, one page.
EMBL Accession No. AYO28916, created on Mar. 30, 2001, European Search Report Reference No. XP 002297424, one page.
EMBL Accession No. BE513408, created on Aug. 8, 2000, European Search Report Reference No. XP 002297422, two pages.
Hubert et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528.
Klein et al., Nat. Med. (1997) 3:402.
Pinto et al., Clin. Cancer Res. (1996) 2(9):1445-1451.
Reiter et al., Proc. Natl. Acad. Sci. USA (1998) 95:1735.
Su et al., Proc. Natl. Acad. Sci. USA (1996) 93:7252.
Afar Daniel E. H.
Challita-Eid Pia M.
Faris Mary
Hubert Rene S.
Jakobovits Aya
Agensys, Inc.
Belyavskyi Michail A
Chan Christina
Morrison & Foerster / LLP
LandOfFree
121P1F1: a tissue specific protein highly expressed in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 121P1F1: a tissue specific protein highly expressed in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 121P1F1: a tissue specific protein highly expressed in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3451936